NCT04665739 2026-04-16
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
48 trialsNCT05773274 2026-04-15
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT04750954 2026-04-13
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05249114 2026-04-13
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
Phase 1 Active not recruiting
NCT05724108 2026-04-13
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04086485 2026-04-07
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT03206060 2026-04-01
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT04727723 2026-03-20
REAL-LU
Novartis
Active not recruiting
NCT06122610 2026-03-19
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 1 Recruiting
NCT07150546 2026-03-02
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Phase 1 Recruiting
NCT04711135 2026-02-12
NETTER-P
Advanced Accelerator Applications
Phase 2 Active not recruiting
NCT04954820 2026-02-05
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT05987176 2026-01-14
NELMAS
Imperial College London
Phase 2 Terminated
NCT03691064 2025-12-23
SALUS
Advanced Accelerator Applications
Active not recruiting
NCT04234568 2025-12-22
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05844332 2025-12-22
LUTATHERA Injection General Use Result Survey
Novartis
Completed
NCT06016855 2025-12-17
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 4 Recruiting
NCT02743741 2025-12-03
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
University Health Network, Toronto
Phase NA Active not recruiting
NCT05178693 2025-11-24
LANTana
Imperial College London
Phase 1 Recruiting
NCT04609592 2025-09-09
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Phase 1 Recruiting
NCT05459844 2025-09-05
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group
Phase 3 Active not recruiting
NCT03457948 2025-09-03
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
Phase 2 Active not recruiting
NCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT06395402 2025-07-22
LUMOD-ID
University of Iowa
Phase 2 Recruiting
NCT07012330 2025-06-10
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
Phase 2 Terminated
NCT04544098 2025-05-02
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT02489604 2025-01-13
LUNET
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT04917484 2024-12-09
DOBATOC
University of Aarhus
Phase 2 Recruiting
NCT02754297 2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2 Active not recruiting
NCT04614766 2024-04-29
SPORE-3
University of Iowa
Phase 1/2 Withdrawn
NCT04385992 2023-06-27
NeoLuPaNET
IRCCS San Raffaele
Phase 2 Completed
NCT05894486 2023-06-08
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
Peking University
Phase 2 Not yet recruiting
NCT05816720 2023-04-18
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Novartis
Completed
NCT05513469 2023-04-07
Radio-Marker
Erasmus Medical Center
Phase NA Unknown
NCT01237457 2023-03-20
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Completed
NCT04949282 2022-12-23
SEPTRALU
Sociedad Española de Medicina Nuclear e Imagen Molecular
Recruiting
NCT01842165 2022-11-10
LUMEN
Jules Bordet Institute
Phase 3 Completed
NCT03590119 2022-11-08
LUTIA
UMC Utrecht
Phase 2/3 Completed
NCT04525638 2022-08-02
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Fundación de investigación HM
Phase 2 Unknown
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT03923257 2021-06-08
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
University of Iowa
Phase 1/2 Withdrawn
NCT04029428 2020-04-01
POLNETS_PRRT
University of Warmia and Mazury
Phase 2 Unknown
NCT02705313 2018-04-09
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Advanced Accelerator Applications
Approved for marketing
NCT01860742 2016-04-05
CASTOR
Jules Bordet Institute
Phase 3 Withdrawn
NCT01201096 2010-09-23
NEO-LEBE
University of Jena
Unknown